Comparative Pharmacology
Head-to-head clinical analysis: ADREVIEW versus PYLORI CHEK BREATH TEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADREVIEW versus PYLORI CHEK BREATH TEST.
ADREVIEW vs PYLORI-CHEK BREATH TEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADREVIEW is a beta-2 adrenergic receptor agonist that stimulates cyclic AMP production, leading to bronchodilation and inhibition of mast cell mediator release.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
0.5 mg intramuscularly every 20 minutes as needed, up to 3 doses, for acute allergic reactions; or 0.1-0.5 mg subcutaneously for bronchospasm.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours; clinically relevant for dosing every 4-6 hours in renal impairment.
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Primarily renal (80-90% as unchanged drug), with minor biliary/fecal elimination (<10%).
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Category C
Category C
Diagnostic Agent
Diagnostic Agent